Celldex Therapeutics, Inc.

CLDX

$27.76

Name : Celldex Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,844,637,312.00

EPSttm : -3.38

Celldex Therapeutics, Inc.

$27.76

5.63%

$1.48

Float Short %

10.64

Margin Of Safety %

Put/Call OI Ratio

0.67

EPS Next Q Diff

-0.04

EPS Last/This Y

-1.13

EPS This/Next Y

-0.83

Price

26.29

Target Price

54.54

Analyst Recom

1.53

Performance Q

-0.38

Relative Volume

0.99

Beta

1.25

Ticker: CLDX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-08	CLDX	29.8	0.65	0.04	4105
2025-12-09	CLDX	28.11	0.64	1.09	4130
2025-12-10	CLDX	28.19	0.72	3.82	4170
2025-12-11	CLDX	27.94	0.73	0.17	4210
2025-12-12	CLDX	27.52	0.73	0.00	4217
2025-12-15	CLDX	27.08	0.73	0.00	4225
2025-12-16	CLDX	26.69	0.73	0.12	4235
2025-12-17	CLDX	25.76	0.72	0.02	4241
2025-12-18	CLDX	25.3	0.73	1.50	4232
2025-12-19	CLDX	25.61	0.73	1.30	4243
2025-12-22	CLDX	27.28	0.34	0.01	1174
2025-12-23	CLDX	26.6	0.29	4.82	1311
2025-12-26	CLDX	26.41	0.36	0.12	1393
2025-12-29	CLDX	26.01	0.36	999.99	1412
2025-12-30	CLDX	26.43	0.37	0.00	1424
2025-12-31	CLDX	27.18	0.37	0.31	1424
2026-01-02	CLDX	27.01	0.36	168.00	1464
2026-01-05	CLDX	25.61	0.67	0.56	1800
2026-01-06	CLDX	26.29	0.67	0.00	1812
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-08	CLDX	29.80	-38.7	-	-3.58
2025-12-09	CLDX	28.09	-38.7	-29.2	-3.58
2025-12-10	CLDX	28.09	-38.7	-55.7	-3.58
2025-12-11	CLDX	27.94	-38.7	-50.8	-3.58
2025-12-12	CLDX	27.51	-38.7	-47.4	-3.58
2025-12-15	CLDX	27.09	-38.7	-47.6	-3.58
2025-12-16	CLDX	27.09	-38.7	-54.7	-3.58
2025-12-17	CLDX	25.77	-38.7	-38.6	-3.58
2025-12-18	CLDX	25.31	-38.7	-45.8	-3.58
2025-12-19	CLDX	25.62	-38.7	-61.1	-3.58
2025-12-22	CLDX	27.19	-38.7	-83.8	-3.58
2025-12-23	CLDX	26.54	-38.7	-42.3	-3.58
2025-12-26	CLDX	26.42	-38.7	-47.3	-3.58
2025-12-29	CLDX	26.02	-38.7	-47.8	-3.58
2025-12-30	CLDX	26.41	-38.7	-61.1	-3.58
2025-12-31	CLDX	27.15	-38.7	-67.1	-3.58
2026-01-02	CLDX	27.00	-38.7	-51.5	-3.58
2026-01-05	CLDX	25.60	-38.7	-30.4	-3.58
2026-01-06	CLDX	26.29	-38.7	-67.1	-3.58
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-08	CLDX	-2.80	-3.01	13.70
2025-12-09	CLDX	-2.80	-3.01	13.70
2025-12-10	CLDX	-2.80	-3.01	13.44
2025-12-11	CLDX	-2.80	-3.01	13.44
2025-12-12	CLDX	-2.80	-3.01	13.44
2025-12-15	CLDX	-2.80	-3.01	13.44
2025-12-16	CLDX	-2.81	-3.01	13.44
2025-12-17	CLDX	-2.81	-3.01	13.44
2025-12-18	CLDX	-2.81	-3.01	13.44
2025-12-19	CLDX	-2.81	-3.01	13.44
2025-12-22	CLDX	-2.81	-3.01	13.44
2025-12-23	CLDX	-2.81	-3.01	13.44
2025-12-26	CLDX	-2.77	-3.01	10.64
2025-12-29	CLDX	-2.77	-2.99	10.64
2025-12-30	CLDX	-2.77	-2.99	10.64
2025-12-31	CLDX	-2.77	-2.99	10.64
2026-01-02	CLDX	-2.77	-2.99	10.64
2026-01-05	CLDX	-2.77	-2.99	10.64
2026-01-06	CLDX	-2.77	-2.99	10.64
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.01

Avg. EPS Est. Current Quarter

-0.99

Avg. EPS Est. Next Quarter

-1.05

Insider Transactions

-2.77

Institutional Transactions

-2.99

Beta

1.25

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-73.1

Target Price

54.54

P/E

Forward P/E

PEG

P/S

671.65

P/B

2.92

P/Free Cash Flow

EPS

-3.38

Average EPS Est. Cur. Y

-3.58

EPS Next Y. (Est.)

-4.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-8635.85

Relative Volume

0.99

Return on Equity vs Sector %

-64.6

Return on Equity vs Industry %

-49.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-67.1

Celldex Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 186

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today

news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance

stock history CLDX – Celldex Therapeutics, Inc. invest stock market

stock prices CLDX premarket after hours

ticker CLDX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CLDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y